Zap-70 is a tyrosine kinase involved in B-cell receptor signaling in chronic lymphocytic leukemia cells. 1 Activation of Zap-70 occurs after phosphorylation of specific tyrosine residues. 2 Dephosphorylation of tyrosine-292, a negative regulatory site, on Zap-70 also activates the kinase activity. 3 Although many of the binding partners of low molecular weight phosphotyrosine phosphatase (LMWPTP) have been characterized, the biological function of LMWPTP remains vague. Although not well characterized in chronic lymphocytic leukemia, overexpression of LMWPTP is generally associated with a proliferative phenotype. 4 LMWPTP has been shown to interact with several tyrosine kinases including the platelet-derived growth factor receptor, the macrophage colony-stimulating factor receptor, the insulin receptor, the Eph receptor, and the epidermal growth factor receptor. 5 Since LMWPTP also interacts with Zap-70, 3 we followed the expression of activated Zap-70 and LMWPTP in a patient with chronic lymphocytic leukemia.
Case description
A 58-year-old Native American school teacher was diagnosed with Rai Stage 0 chronic lymphocytic leukemia (CLL) in 1996 when she presented with chronic fatigue and a total white blood count of 31 600/ml with 77% lymphocytes. Flow cytometry confirmed clonal evidence for kappa-restricted CD5 þ lymphocytosis, consistent with a B-CLL. Analysis of genomic aberrations by fluorescence in situ hybridization (FISH) with probes specific for ATM, chromosome 12 centromere, RB-1, D13S25, and p53 loci revealed evidence of a deletion in 13q14 involving the Rb-1 and D13S25 loci. By 1999, her total white blood count was greater than 90 000/ml. She displayed no other symptoms other than fatigue and did not require therapy until 2002 when she developed lymphadenopathy, symptomatic splenomegaly, and night sweats. She was treated with six cycles of chlorambucil and prednisone with a partial response in lymphocyte count, spleen size, and lymph node shrinkage. Although her total white blood count fluctuated between 100 000 and 200 000/ml, her disease remained stable for the next 6 months. She was subsequently treated with six cycles of fludarabine for progressive lymphocytosis and lymphadenopathy. Her lymphadenopathy responded to fludarabine, but she then developed steroid-refractory idiopathic thrombocytopenic purpura (ITP) that required treatment with splenectomy. She has since required chemotherapy mainly for treatment of her immune-mediated thrombocytopenia.
Results
We made whole cell lysate from isolated B lymphocytes from the patient described above from peripheral blood collected from 6/26/2003 to 5/13/2004. We assessed expression of Zap-70 immunochemically. We determined if Zap-70 was an active kinase with the phosphorylated tyrosine 493 Zap-70 antibody. We also assessed expression of low molecular weight phosphotyrosine phosphatase. Prior to initiating chemotherapy, the patient expressed Zap-70, phosphorylated zap-70, and low molecular weight phosphotyrosine phosphatase. Expression of phosphorylated Zap-70 was no longer present after initial assessment. There appears to be a doublet form of Zap-70 from the sample collected on 8/18/03, but this form did not react with the phospho-tyrosine 493 Zap-70 antibody. Results from Figure 1 are summarized in Table 1 
Case discussion
CLL is generally an indolent disease. However, two distinct CD5 þ B-CLL cell types have correlated closely with disease progression: a cell which has been through the germinal center and a cell which has not been through the germinal center and therefore, retains the naïve B-cell phenotype. Patients whose CLL cells have acquired somatic mutations of the immunoglobulin genes tend to have longer life expectancies compared to patients with cells of unmutated status, corresponding with proliferation of naïve B-cell clones. 6 It is unclear if early treatment of the patients with cells of unmutated status dramatically changes the natural history of their disease. Since CLL remains largely an incurable disease, markers which help predict which patients benefit from treatment remains a diagnostic goal. The method for determining the mutational status of the immunoglobulin genes is laborious and expensive; many attempts have been made to find better surrogate markers of mutational status. Since the commercial availability of determining cytogenetic abnormalities by a CLL-specific FISH panel, about 80% of patients with CLL now have identifiable cytogenetic abnormalities. 7 Patients with a deletion in 17p tend to have the worse overall survival compared to patients with a deletion in 13q as an isolated finding. 7 Patients with a deletion in 11q or normal cytogenetics as defined by FISH have an intermediate prognosis compared to the other cytogenetic abnormalities, although a recent study from Birmingham suggests that patients with the 11q deletion may have an additional ATM mutation, which has an independent impact on overall survival (ASH oral presentation 2004).
This method of categorizing patients with CLL into different prognostic groups has helped hematologists prioritize the frequency of the interval between office visits. Ideally, information gathered from placing patients into these different risk categories should correlate with predicting a need for early treatment. Early treatment of the disease would ideally translate into a prolonged disease-free survival. However, this has not held true in the individual patient. Additional markers like CD38 have been convenient to assess as this information was easily obtained by flow cytometry. Recently, Zap-70 expression has emerged as a better predictor for early treatment requirement 8 compared to CD38 or mutational status, but results obtained from flow cytometry have been inconsistent, thus making it difficult to adapt for commercial use. Zap-70 is a tyrosine kinase receptor with two Src homology 2 (SH2) domains and a C-terminal catalytic domain. 2 It normally participates in T-cell receptor signaling, but also contributes to B-cell receptor signaling in CLL. The aberrant expression of Zap-70 in CLL correlates with an unmutated immunoglobulin status and worse overall survival compared to patients who do not express this protein. 6 The functionality of Zap-70 has not been extensively assessed under nonartificial conditions. An intact or fragmented IgM antibody is usually added to stimulate B-cell receptor ligation, which results in autophosphorylation of Zap-70 and activation of downstream proteins. In this report, we describe the association of low molecular weight phosphotyrosine phosphatase (LMWPTP) expression with pTyr493 Zap-70. Dephosphorylation of Zap-70 at tyrosine position 292 is required for Zap-70 activation. 3 Expression of these proteins by Western blotting goes away with continued treatment of the disease, again correlating with a requirement for treatment when expression of these proteins is present. Table 1 summarizes interpretation and correlation of the results of Western blots for Zap-70, phospho-Tyr 493 Zap-70, and LMWPTP to the clinical history of the patient. Although interrogation of Zap-70 by Western blot may be just as laborious because of a requirement for T-cell depletion, Zap-70 expression by Western blot correlates with at least a 30% Zap-70 expression by flow cytometry. 8 Patients with a deletion in chromosome 13 as a sole cytogenetic abnormality generally have a longer life expectancy than patients with other FISH abnormalities. 7 There was relatively little change over time in the percentage of cells labeled by the two FISH probes for deletion in chromosome 13 (Table 2 ). This patient with Rai Stage 0 CLL fits that profile as it took 6 years before treatment was required for her disease. Although there is evidence to support that Zap-70 expression does not change over time, 8 we show that gradual loss of Zap-70 expression can occur in this patient with continued chemotherapy. In the meantime, this patient no longer expresses either LMWPTP, Zap-70, or pTyr492 Zap-70. 
